For the WD patients with typical clinical symptoms but only single or no heterozygous ATP7B mutation, it is plausible to hypothesize that the copper transporters (CTR1 and/or CTR2) might act as modifier genes to influence the WD phenotype. Here, SLC31A1 is linked to Wilson disease.